{"version":"1.0","provider_name":"Indonesia Tribune","provider_url":"https:\/\/indonesiatribune.com","author_name":"admin","author_url":"https:\/\/indonesiatribune.com\/author\/admin\/","title":"STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment - Indonesia Tribune","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"01dzynJoaH\"><a href=\"https:\/\/indonesiatribune.com\/stalicla-signs-exclusive-in-licensing-agreement-for-late-stage-clinical-neuropsychiatric-and-neurodevelopmental-disorder-treatment\/\">STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/indonesiatribune.com\/stalicla-signs-exclusive-in-licensing-agreement-for-late-stage-clinical-neuropsychiatric-and-neurodevelopmental-disorder-treatment\/embed\/#?secret=01dzynJoaH\" width=\"600\" height=\"338\" title=\"&#8220;STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment&#8221; &#8212; Indonesia Tribune\" data-secret=\"01dzynJoaH\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"PRESS RELEASE STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment The transaction with Novartis reinforces STALICLA\u2019s position as the leading developer of precision medicines for neurodevelopmental disorders and heralds the expansion of its portfolio into wider neuropsychiatric indications Geneva, SWITZERLAND \u2013 9 January 2023, STALICLA SA, a clinical-stage biotech company [\u2026]","thumbnail_url":"https:\/\/ci3.googleusercontent.com\/proxy\/EgEdZWBHfOU8OcPvCw0D-pYoy9vh9DqMWSKQsz7d0HAXcTBETShjalrE6QVOo4JYUNJ_Ap6Fk5Os4E3AIcyfO8pxdkx2wkYR0hc0g_SGXH9y_CF9yevrWX-il7MZlmel_hJXNu8x6yY=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc3NjA2MiM0MDE0NTQ3NDEjNzAwMDEzNjM1"}